Last updated: 07/31/2020 03:10:22

Phase 1 study of GSK2315698 in healthy Japanese subjects

GSK study ID
205911
See study documents
Clinicaltrials.gov ID
NCT02953808
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A single centre, double-blind, randomised, placebo-controlled, and single dose-ascending study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics, of single intravenous doses of GSK2315698 in healthy Japanese subjects
Trial description: This is the first study in which GSK2315698 will be administered in Japanese population. The primary objective of the study is to investigate safety and tolerability, pharmacokinetics, and pharmacodynamics after single intravenous infusion in healthy subjects. This will be a single center, double-blind, randomized, placebo-controlled, dose-ascending study.
Subjects in Cohort 1 will attend 3 dosing sessions, and will be randomized to one of the 3 groups. Each group will receive GSK2315698 and Placebo in a defined sequence. The dose levels of GSK2315698 are set to 10 milligrams (mg) per hour (hr), 20 mg/hr, and 40 mg/hr, to be administered over 1 hour. Dosing sessions 1 and 2, and dosing sessions 2 and 3, will be separated by a washout period of at least 8 and 10 days, respectively.
Subjects in Cohort 2 will attend a single dosing session, and will be randomized to receive either GSK2315698 20 mg/hr or Placebo, over a period of 15 hours.
A sufficient number of subjects will be randomized such that 18 subjects (9 in each cohort) complete the study. The duration of participation for any subject in this study will be approximately 59 days.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Number of subjects with adverse events (AE) and serious adverse events (SAE)

Timeframe: Over a maximum period of approximately 29 days

Number of subjects with abnormalities in clinical laboratory parameters

Timeframe: Over a maximum period of approximately 59 days

Number of subjects with abnormalities in vital sign parameters

Timeframe: Over a maximum period of approximately 59 days

Number of subjects with electrocardiogram (ECG) abnormalities

Timeframe: Over a maximum period of approximately 59 days

Plasma concentration of GSK2315698

Timeframe: Pre-dose and 0.25, 1, 2, 4, 6, 8, 12, 24 hours post-dose in Cohort 1; Day 1 (pre-dose and 0.25, 1, 4, 12, 15, 18, 24 hours post-dose), and Days 5, 8, 14 in Cohort 2

Maximum observed plasma concentration (Cmax) of GSK2315698

Timeframe: Pre-dose and 0.25, 1, 2, 4, 6, 8, 12, 24 hours post-dose in Cohort 1; Day 1 (pre-dose and 0.25, 1, 4, 12, 15, 18, 24 hours post-dose), and Days 5, 8, 14 in Cohort 2

Area under the concentration-time curve from pre-dose to 24 hours (AUC0-24) of GSK2315698

Timeframe: Pre-dose and 0.25, 1, 2, 4, 6, 8, 12, 24 hours post-dose in Cohort 1; Day 1 (pre-dose and 0.25, 1, 4, 12, 15, 18, 24 hours post-dose), and Days 5, 8, 14 in Cohort 2

Time to maximum observed plasma drug concentration (Tmax) of GSK2315698

Timeframe: Pre-dose and 0.25, 1, 2, 4, 6, 8, 12, 24 hours post-dose in Cohort 1; Day 1 (pre-dose and 0.25, 1, 4, 12, 15, 18, 24 hours post-dose), and Days 5, 8, 14 in Cohort 2

Cohort 2: Plasma concentration of GSK2315698 at 15 hours (C15hr)

Timeframe: Pre-dose and 0.25, 1, 4, 12, and 15 hours post-dose in Cohort 2

Change from Baseline in blood concentration of serum amyloid P component (SAP)

Timeframe: Day 1 (pre-dose and 0.25, 1, 2, 4, 6, 8, 12, 24 hours post-dose), Day 5, and Day 8 in Cohort 1; Day 1 (pre-dose and 0.25, 1, 4, 12, 15, 18, 24 hours post-dose), and Days 5, 8, 14 in Cohort 2

Minimum blood concentration (Cmin) of SAP

Timeframe: Day 1 (pre-dose and 0.25, 1, 2, 4, 6, 8, 12, 24 hours post-dose), Day 5, and Day 8 in Cohort 1; Day 1 (pre-dose and 0.25, 1, 4, 12, 15, 18, 24 hours post-dose), and Days 5, 8, 14 in Cohort 2

Time to minimum observed concentration (Tmin) of SAP

Timeframe: Day 1 (pre-dose and 0.25, 1, 2, 4, 6, 8, 12, 24 hours post-dose), Day 5, and Day 8 in Cohort 1; Day 1 (pre-dose and 0.25, 1, 4, 12, 15, 18, 24 hours post-dose), and Days 5, 8, 14 in Cohort 2

Cohort 2: Concentration of SAP at 15 hours (C15hr)

Timeframe: Pre-dose and 0.25, 1, 4, 12, and 15 hours post-dose in Cohort 2

Secondary outcomes:
Not applicable
Interventions:
  • Drug: Placebo
  • Drug: GSK2315698
    • Enrollment:
    18
    Primary completion date:
    2016-22-12
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Hiroko Ino, Yohei Doi, Lia Liefaard, Chao Chen, Louise Cookson, Hiroshi Itoh, Harue Igarashi, Atsushi Nakano.Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single intravenous dose of miridesap in healthy Japanese subjects.Clin Pharmacol Drug Devel.2019;8(5):612-618 DOI: 10.1002/cpdd.631; published: https://doi.org/10.1002/cpdd.631 PMID: 30556959
    Medical condition
    Amyloidosis
    Product
    miridesap
    Collaborators
    Not applicable
    Study date(s)
    November 2016 to December 2016
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Male
    Age
    20 - 64 years
    Accepts healthy volunteers
    Yes
    • Participant must be 20 to 64 years of age inclusive, at the time of signing the informed consent
    • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor if required agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
    • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data
    • Clinically abnormal hypotonia or hyperpiesia as determined by the investigator
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Participant must be 20 to 64 years of age inclusive, at the time of signing the informed consent
    • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor if required agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
    • Peripheral veins suitable for venous blood sampling and cannulation
    • Body weight >=50 kilograms (kg) and body mass index (BMI) within the range 18.5-24.9 kg per meter (m) squared (inclusive)
    • Male: A Japanese male participant must agree to use contraception during the treatment period and until follow up visit
    • Capable of giving signed informed consent
    Exclusion criteria:
    • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data
    • Clinically abnormal hypotonia or hyperpiesia as determined by the investigator
    • Previous surgical procedures on the upper digestive tract including cholecystectomy (gallbladder removal), and/or cholelithotomy (gallstone removal)
    • Alanine Aminotransferase (ALT) >1.5 multiplied by upper limit of normal (ULN)
    • Bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
    • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
    • QTcF >450 millisecond (msec) QTcF is either machine-read or manually over-read. The specific formula that will be used to determine eligibility and discontinuation for an individual subject should be determined prior to initiation of the study. In other words, several different formulae cannot be used to calculate the corrected QT interval (QTc) for an individual subject and then the lowest QTc value used to include or discontinue the subject from the trial. For purposes of data analysis, QTcF, another QT correction formula, or a composite of available values of QTc will be used
    • Past or intended use of over-the-counter or prescription medication including herbal medications within 14 days prior to dosing. Specific study-defined medications may be allowed
    • History of donation of blood or blood products >=400 mL within 3 months or >=200 mL within 1 month prior to screening
    • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day
    • Current enrollment or past participation within the last 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) before signing of consent in this or any other clinical study involving an investigational study treatment or any other type of medical research
    • The subject is positive for Serological test for syphilis (Rapid plasma reagin test [RPR] and Treponema pallidum Latex Agglutination [TPLA]), Human immunodeficiency virus (HIV) antigen/antibody, Hepatitis B surface antigen (HbsAg), Hepatitis C virus (HCV) antibody, or Human T-cell lymphotropic virus type 1 (HTLV-1) antibody at screening
    • Positive pre-study drug screen
    • Regular use of known drugs of abuse
    • Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of >14 units for males. One unit is equivalent to 350 mL of beer, 150 mL of wine or 45 mL of 80 proof distilled spirits
    • Smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening; Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates participation in the study

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Tokyo, Japan, 171-0014
    Status
    Study Complete
    Contact us

    Study documents

    Protocol
    Available language(s): English
    Download document(s)
    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    2016-22-12
    Actual study completion date
    2016-22-12

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website